Computational prediction of interactions between Paxlovid and prescription drugs
Yeji Kim, Jae Yong Ryu, Hyun Uk Kim, Sang Yup Lee · Proceedings of the National Academy of Sciences · 2023
Pfizer's Paxlovid has recently been approved for the emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19. Drug interactions can be a serious medical problem for COVID-19 patients with underlying medical conditions, such as hypertension and diabetes, who have likely been taking other drugs. Here, we use deep learning to predict potential drug-drug interactions between Paxlovid components (nirmatrelvir and ritonavir) and 2,248 prescription drugs for treating various diseases.